MARK2 Kinase Inhibition for Proteotoxic Stress in Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack a kinase that phosphorylates eukaryotic initiation factor 2 alpha (eIF2α) in response to protein unfolding stress, which is a common theme in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
Innovation Solution
The identification of microtubule affinity-regulating kinase 2 (MARK2) as a direct kinase for eIF2α, which phosphorylates eIF2α in response to proteotoxic stress, and the development of compounds of formula (I) that inhibit MARK2 kinase activity to treat diseases associated with eIF2α phosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MARK2 kinase activity is inhibited, then eIF2α phosphorylation is reduced and proteotoxic stress is alleviated, but the mechanism to sense protein misfolding stress is lost
Solution Approach 1:
The patent introduces MARK2 as an intermediary kinase that mediates the stress response pathway. MARK2 receives stress signals and transduces them to eIF2α phosphorylation, serving as a controllable mediator between stress sensing and translational regulation.
Solution Approach 2:
The patent modulates the phosphorylation parameter of eIF2α by inhibiting MARK2 kinase activity. This parameter change (reduced phosphorylation) directly alleviates proteotoxic stress while maintaining the ability to sense stress through alternative mechanisms.
2Reliability
If eIF2α phosphorylation is increased, then translation is attenuated and stress response is enhanced, but protein homeostasis is disrupted
Solution Approach 1:
The patent applies partial inhibition of MARK2 kinase activity rather than complete suppression. This partial action maintains sufficient eIF2α phosphorylation for stress response while preventing excessive phosphorylation that would disrupt protein homeostasis.
Solution Approach 2:
The patent establishes a feedback mechanism where MARK2 activity is regulated based on stress conditions. Under normal conditions, MARK2 maintains baseline eIF2α phosphorylation for homeostasis; under stress, the feedback loop activates enhanced phosphorylation for stress response.
3Loss of information
If MARK2 is identified as the kinase, then the stress response pathway is clarified, but the complexity of kinase identification increases
Solution Approach 1:
The patent segments the stress response pathway into distinct functional components: stress sensing, MARK2 kinase activation, and eIF2α phosphorylation. This segmentation simplifies the identification process by isolating MARK2 as the critical intermediary step.
Solution Approach 2:
The patent uses computational modeling and predictive algorithms to identify MARK2 as the likely kinase, copying and extending existing knowledge from related pathways. This approach reduces the experimental complexity by leveraging bioinformatic predictions to guide validation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Inhibiting MARK2 kinase activity reduces the phosphorylation of eIF2α, thereby alleviating proteotoxic stress and potentially treating neurodegenerative diseases such as ALS.
Implementation Method 1
phosphorylation of serine 51 (51S) of its alpha subunit (eIF2α), with increased phosphorylation resulting in global attenuation of the translation of most transcripts
Data Source
AI summary
The identification of a direct kinase of eukaryotic initiation factor 2 alpha (eIF2α), microtubule affinity-regulating kinase 2 (MARK2), which phosphorylates eIF2α in response to proteotoxic stress, is provided. Inhibitors of MARK2 and their use in treating neurodegenerative disease, including Alzheimer's disease, Parkinson disease, Creutzfeldt-Jakob disease, Huntington's disease, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), also are disclosed.